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show that genetic ablation of CSF1 in colorectal cancer cells reduces the influx of
immunosuppressive CSF1R+ TAMs within tumors. This reduction in CSF1-dependent
TAMs resulted in increased CD8+ T cell attack on tumors, but its effect on tumor growth was
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Introduction
Tumors grow in immunocompetent hosts despite the ability of  the adaptive immune system to rec-
ognize and kill cancer cells. In part this is attributable to the phenomenon of  immunosuppression. 
Tumor-associated macrophages (TAMs) are among the most abundant nontransformed cell types in 
solid cancers (1–4), and growing evidence suggests that TAMs can promote cancer progression and 
therapeutic resistance in a wide range of  human malignancies (5–15). TAMs can be acutely targeted 
via the inhibition of  colony-stimulating factor-1 (CSF1 or M-CSF) or its receptor, CSF1R (CD115), 
and in preclinical studies, CSF1/CSF1R inhibitors reduce tumor growth in murine tumor models 
(15–20). Further, CSF1 inhibitors are currently being tested in clinical trials (21), of  which the most 
advanced is the small-molecule CSF1R inhibitor PLX3397 (22). Although early preclinical data sug-
gested good tolerability and promising effects, CSF1R inhibitors have shown very limited antitumor 
effects in patients (23). Further, blocking the CSF1 pathway can also cause systemic effects not limited 
to macrophage depletion, such as rebound hematopoiesis. The current lack of  understanding of  the 
mechanism that regulates CSF1-driven tumor progression raises concerns regarding the potential clini-
cal utility of  these therapeutic strategies.
Regulatory T cells (Treg cells) are a subpopulation of  lymphocytes that are critical in maintaining tol-
erance to self-antigens and innocuous foreign antigens under physiological conditions, but can also be co-
opted by tumors to escape immunity (24). Phosphoinositide 3-kinase δ (PI3Kδ) is abundant in lymphocytes 
(25) and is activated by antigen, cytokine, and growth factor receptors (26). Recent evidence has shown 
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ablation of CSF1 in colorectal cancer cells reduces the influx of immunosuppressive CSF1R+ TAMs 
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tumors, but its effect on tumor growth was limited by a compensatory increase in Foxp3+ Treg cells. 
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that genetic inactivation of  PI3Kδ in mice protects against a wide range of  solid tumors (27). This immu-
nomodulatory effect was due to the inactivation of  PI3Kδ in CD4+Foxp3+ Treg cells, unleashing CD8+ 
cytotoxic T lymphocytes which could then induce tumor regression (27). The PI3Kδ inhibitor, idelalisib 
(Zydelig, Gilead) has proven highly effective for the treatment of  chronic lymphocytic leukemia (26), and 
exerts its main effect by blocking the interactions between lymphocytic leukemia cells and stromal cells in 
their lymphoid niche. However, the extent to which PI3Kδ inhibitors may have more widespread utility in 
the treatment of  solid tumors is only beginning to be explored (25).
CSF1R+ TAMs and Foxp3+ Treg cells have been shown to influence tumor growth via a number of  dif-
ferent molecular mechanisms, some acting directly on the tumor cells themselves, and some via inhibition 
of  effector cells of  the immune system, most notably CD8+ cytotoxic T lymphocytes. However, the extent 
to which these mechanisms form a partially redundant cellular network contributing robustness to tumor 
immunosuppression and a compensatory network contributing resistance to immunotherapy is unclear. In 
this study we provide evidence that the growth of  adenocarcinomas in a mouse model of  colorectal cancer 
was partially dependent upon suppression of  CD8+ T cells by CSF1R+ macrophages recruited by tumor 
cell–derived CSF1. However, genetic ablation of  CSF1 in the tumor cells, or pharmacological blockade of  
CSF1R by PLX3397, resulted in an increased accumulation of  Foxp3+ Treg cells, limiting an effective CD8+ 
T cell response against the tumor. Vice versa, depletion of  Foxp3+ Treg cells resulted in a large accumulation 
of  CSF1R+ macrophages, suppressive to CD8+ T cell function. Importantly, genetic inactivation of  PI3Kδ in 
Foxp3+ Treg cells hugely sensitized solid tumors to depletion of  CSF1R+ TAMs. Further, combined inhibi-
tion of  CSF1R and PI3Kδ by PLX3397 and idelalisib, respectively, substantially and synergistically inhib-
ited tumor growth. These findings highlight the potential for TAMs and Treg cells to each overcome the 
individual blockade of  the other, and provide a rationale for a new form of  combinatorial immunotherapy.
Results
Tumor cell–derived CSF1 promotes solid tumor growth and recruits TAMs. Several different cell types have the 
potential to produce CSF1 within the tumor microenvironment, such as stromal fibroblasts, immune cells, 
and tumor cells themselves (28). To more clearly define the extent to which tumor cell–derived CSF1 affects 
macrophage biology, we first asked whether selected mouse tumor cell lines — the LLC lung carcinoma, 
4T1 mammary carcinoma, MC38 colorectal adenocarcinoma, and TRAMP-C1 prostate adenocarcinoma 
cells — secrete functional CSF1. We cultured bone marrow–derived macrophages (BMDMs) in the pres-
ence of  supernatant collected from the different tumor cells. Conditioned media derived from all the tested 
tumor cell lines (LLC, 4T1, MC38, and TRAMP-C1) promoted the survival of  primary BMDMs (Figure 
1A). We tested tumor supernatants for the presence of  different growth factors and cytokines known to affect 
the survival of  BMDMs. ELISA analysis indicated that LLC, 4T1, MC38, and TRAMP-C1 secreted high 
levels of  CSF1 into the culture supernatant in a fashion that correlated with the relative effects of  their con-
ditioned medium on BMDM survival (Figure 1, B and C). To determine whether the major survival factor 
responsible for the observed effect was CSF1, we tested whether neutralization of  CSF1 in culture superna-
tants abrogates the survival of  the BMDMs in the presence of  MC38 tumor supernatant. Strikingly, CSF1 
accounted for the entirety of  the macrophage survival effect of  MC38 culture supernatants (Figure 1D).
Having found that high levels of  CSF1 are secreted into the culture supernatant by a range of  mouse 
solid tumor cell lines, we asked whether tumor cell–derived CSF1 is the predominant factor supporting 
TAM survival in vivo. To this end, we disrupted the gene encoding CSF1 using CRISPR/Cas9 mutagen-
esis in MC38 cells. We confirmed that Csf1–/– MC38 cells are not able to secrete CSF1 into the culture 
supernatant (Figure 1E), and cannot support macrophage survival in vitro (Figure 1F). We detected no 
significant difference between the growth rates of  parental (WT) and Csf1–/– MC38 cells in vitro (Supple-
mental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.120631DS1), or when CSF1 was neutralized within WT tumor cell line cultures (Supplemental 
Figure 1B), arguing against an autocrine role of  CSF1 on tumor cells themselves. However, we observed 
impaired growth of  Csf1–/– tumor cells compared with the parental MC38 cells in vivo when implanted 
into C57BL/6 mice, although tumor rejection was incomplete (Figure 1, G and H). When we isolated and 
analyzed the immune cell infiltrates of  primary tumors removed at day 21 after implantation, we found 
a significant reduction in the F4/80+ Ly6C– leukocyte population in Csf1–/– tumors compared with WT 
tumors (Figure 1, I and J). Moreover, the decrease in the number of  CSF1R+ cells among the F4/80+ cell 
population was even more pronounced between the 2 genotypes (Figure 1, I and K). Deletion of  CSF1 in 
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tumor cells also resulted in significantly reduced numbers of  macrophages expressing CD206 and CD163, 
markers which are present on M2-polarized TAMs (Supplemental Figure 2, A–C). These results indicate 
that tumor cell–derived CSF1 has an important role in promoting solid tumor growth and in recruiting 
CSF1R+ TAMs into the tumor microenvironment but raise the possibility that other factors contribute to 
residual immunosuppression in the absence of  tumor cell–derived CSF1.
Tumor cell–derived CSF1 recruits TAMs, which act through the inhibition of  CD8+ T cells. We were able to 
detect CSF1R+ cells colocalizing with CD8+ cells in the primary MC38 tumors and this observation led us 
to ask whether such cells might influence CD8+ T cell function. To test this, we implanted Csf1–/– tumor cells 
into Rag2–/– mice, deficient in T and B cells of  the adaptive immune system. Strikingly, growth of  WT and 
Csf1–/– tumors in Rag2–/– animals was similar, in contrast to their growth in immunocompetent hosts (Figure 
2A). Furthermore, the growth defect of  the Csf1–/– tumors was completely reversed following antibody-
mediated depletion of  CD8+ T cells (Figure 2D). We confirmed the depletion of  F4/80+ and CSF1R+ 
TAMs in Csf1–/– MC38 tumor–bearing mice and the depletion of  CD8+ T cells in Rag2–/– animals or anti-
body-treated mice by flow cytometry (Figure 2, B, C, E, and F). Although the recruitment of  TAMs was 
unaffected by loss of  CD8+ T cells (Figure 2, B and E), we found large increases in CD8+ T cell numbers in 
the primary Csf1–/– tumors compared with the WT tumors (Figure 2, C and F). These data strongly indicate 
that tumor cell–derived CSF1 drives TAM-dependent suppression of  antitumor CD8+ T cell responses.
Figure 1. Tumor cell–derived CSF1 promotes tumor growth and recruits CSF1R+ tumor-associated macrophages. (A and B) Representative graph (A) 
and quantification at day 3 (B) of the number of BMDMs cultured in the presence of complete media supplemented with recombinant CSF1 or tumor-
derived supernatant from LLC (lung), 4T1 (breast), MC38 (colon), and TRAMP (prostate) cancer cell lines. (C) Concentration of CSF1 in the tumor cell 
supernatants measured by ELISA. (D) Quantification of BMDMs cultured in the presence of MC38 tumor cell–derived supernatant with or without anti-
CSF1 neutralizing antibody. (E) Concentration of CSF1 in the WT and CRISPR/Cas9-enginered Csf1–/– MC38 tumor cell supernatants measured by ELISA. 
(F) Survival of BMDMs cultured in the presence of WT and Csf1–/– MC38 tumor cell–derived supernatant. (G and H) In vivo growth curves (G) and tumor 
masses (H) of WT and Csf1–/– MC38 tumor cells in WT mice following s.c. injections at day 0. (I–K) Representative dot plots (I) and quantification of the 
F4/80+ Ly6C– (J) and CSF1R+ of F4/80+ (K) immune cell infiltrates of WT and Csf1–/– MC38 tumors derived from WT mice at day 21. Graphs show mean 
± SEM of data from at least 3 independent experiments or 5 to 10 individual mice per group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., 
non-significant by Student’s t test or 2-way ANOVA.
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Given the observation that CSF1R+ TAMs limit adaptive immunity, we asked whether the immu-
nosuppressive effect of  tumor cell–derived CSF1 was specifically dependent upon expression or secre-
tion of  certain molecules by macrophages. To this end, we isolated CSF1R+ TAMs from the primary 
MC38 tumors using a discontinuous Percoll gradient and CD115-based positive magnetic selection. 
With this approach, primary TAMs could be cultured for a few days in the presence of  tumor-condi-
tioned media and showed similar morphology to primary BMDMs cultured in the presence of  tumor 
supernatant (Figure 2G).
Tumor cells frequently express programmed cell death-ligand 1 (PD-L1), facilitating their escape from 
the immune system (29). However, little is known about the role of  PD-L1 on TAMs, so we next tested the 
expression of  PD-L1 on the primary MC38 tumor-isolated macrophages. As shown on Figure 2H, tumor-
derived primary TAMs strongly expressed PD-L1 compared with naive BMDMs. We asked whether this 
is in part attributable to a factor secreted by tumor cells. Remarkably, culturing BMDMs in the presence of  
tumor cell–derived conditioned media significantly increased the ratio of  cells expressing PD-L1 on their 
surface (Figure 2H). Furthermore, in the culture supernatants of  CSF1R+ TAMs we were also able to detect 
high amounts of  TGF-β1 (1.48 ± 0.14 ng/ml/10
6 cells) capable of  inhibiting lymphocyte proliferation and 
function. As a consequence, primary TAMs and tumor re-educated BMDMs — but not naive BMDMs 
— could strongly suppress CD8+ T lymphocyte proliferation in vitro (Figure 2, I and J). Taken together, 
Figure 2. CSF1R+ tumor-associated macrophages inhibit CD8+ T cells of the adaptive immune system. (A) In vivo growth curves of WT and Csf1–/– MC38 
tumor cells implanted s.c. at day 0 into WT and Rag2–/– mice. (B and C) Quantification of the F4/80+ (B) and CD8+ (C) immune cells infiltrating the WT and 
Csf1–/– tumors isolated from the WT and Rag2–/– mice at day 21. (D) WT and Csf1–/– MC38 primary tumor masses removed at day 21 from WT mice treated 
with anti-CD8 antibody or control antibody. (E and F) Quantification of the CSF1R+ (E) and CD8+ (F) immune cells infiltrating the WT and Csf1–/– tumors 
isolated from the WT mice treated with anti-CD8 or control antibody at day 21. (G and H) Representative photomicrographs of (G) and PD-L1 expression 
on (H) BMDMs cultured in the presence of recombinant CSF1 or MC38 tumor supernatant and of primary CSF1R+ TAMs isolated from the MC38 primary 
tumors. (I and J) Representative flow panels (I) and quantification (J) of the in vitro proliferation of CD8+ lymphocytes co-cultured with BMDMs (as treated 
above) or CSF1R+ TAMs isolated from the MC38 tumors. Graphs show mean ± SEM of data from at least 3 independent experiments or 5–6 individual mice 
per group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., non-significant by Student’s t test or 2-way ANOVA. Scale bars: 50 μm.
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these data indicate that CSF1R+ TAMs express PD-L1, secrete TGF-β1, and are capable of  limiting CD8
+ 
T lymphocyte proliferation ex vivo, but other sources of  immunosuppression may contribute to the failure 
of  total tumor rejection with CSF1 ablation alone.
Depletion of  CSF1R+ macrophages synergizes with genetic ablation of  Foxp3+ Treg cells and with deletion of  
PI3Kδ specifically in the Foxp3+ Treg compartment. To determine the dependence of  MC38 tumors on Treg-
mediated immunosuppression, we depleted Treg cells from MC38 tumor-bearing Foxp3DTR mice treated 
with 25 μg/kg diphtheria toxin by intraperitoneal injection on days 3, 7, 10, 14, and 17 after tumor 
injection. Treg depletion led to reduced MC38 tumor growth, similar to the effects of  deleting MC38-
derived CSF1 alone, indicating that Treg cells were also an important component of  immunosuppres-
sion in the MC38 model (Figure 3, A and B). Strikingly, deletion of  both tumor cell–derived CSF1 and 
Foxp3+ Treg cells caused almost complete tumor rejection (Figure 3, A and B); half  of  the mice were 
completely tumor-free. Depletion of  Treg cells alone led to significant increases in F4/80+ and CSF1R+ 
TAMs (Figure 3, C–E) and deletion of  tumor-derived CSF1 caused significant increases in intratumoral 
Foxp3+ cells (Figure 3F). This suggested that each of  these 2 immunosuppressive mechanisms might 
compensate for the loss of  the other, and that inhibition of  both was required to unleash full CD8+ 
T cell–mediated attack on the tumor, thereby leading to complete tumor rejection. In support of  this 
idea, we found that combined deletion of  tumor-derived CSF1 and Foxp3+ Treg cells produced a supra-
additive effect on the number of  tumor-associated CD8+ T cells (Figure 3G).
Figure 3. Depletion of CSF1R+ macrophages synergizes with genetic ablation of Foxp3+ Treg cells. (A and B) In vivo growth curves (A) and primary tumor 
masses at day 21 (B) of WT and Csf1–/– MC38 tumor cells implanted s.c. at day 0 into WT and Foxp3DTR mice treated with 25 μg/kg diphtheria toxin (DTx) 
i.p. (C–G) Representative flow panels (C) and quantification of the F4/80+ (D) CSF1R+ (E), Foxp3+ (F), and CD8+ (G) immune cell infiltrates of WT and Csf1–/– 
MC38 tumors isolated from WT and Foxp3DTR mice treated with DTx. Graphs show mean ± SEM of data from 10 individual mice per group. **P < 0.01; ***P 
< 0.001; ****P < 0.0001 by 2-way ANOVA.
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Recent studies indicate that PI3Kδ plays an important role in the maturation of  Foxp3+ Treg cells 
and that this effect can supercede a smaller role for PI3Kδ in CD8+ T cell function, such that tumors 
relying heavily on Treg -mediated suppression of  CD8+ T cells for growth can be inhibited by deletion 
of  PI3Kδ (27). We investigated a potential role for PI3Kδ in the MC38 model using mice with a Treg-
specific deletion of  PI3Kδ. Foxp3YFP-Cre Pik3cdfl/fl mice had reduced numbers of  intratumoral Foxp3+ 
Treg cells and behaved similarly to the Foxp3DTR mice, both in terms of  their partial resistance to tumor 
growth, a compensatory increase in F4/80+ and CSF1R+ TAMs, and their combinatorial effects with 
deletion of  tumor-derived CSF1 (Figure 4, A–E). Thus, Csf1–/– tumors had greatly reduced volume and 
mass when grown in Foxp3YFP-Cre Pik3cdfl/fl mice (Figure 4, A and B). Deletion of  both tumor-derived 
CSF1 and PI3Kδ in Treg cells produced supra-additive increases in the intratumoral CD8+ T cell popu-
lation and a striking synergistic augmentation of  their function in terms of  IFN-γ production (Figure 
4, D, G, and H).
Combined inhibition of  CSF1R and PI3Kδ effectively blocks solid tumor immunosuppression. Our observa-
tions that combined depletion of  Foxp3+ Treg cells and CSF1R+ TAMs can lead to very effective inhibi-
tion of  tumor growth led us to explore the potential for combined pharmacological inhibition of  CSF1R 
and PI3Kδ, in particular to investigate whether compensatory immunosuppression between CSF1R+ 
Figure 4. Depletion of CSF1R+ macrophages synergizes with Foxp3+ Treg cell–specific deletion of PI3Kδ. (A and B) In vivo growth curves (A) and 
primary tumor masses at day 21 (B) of WT and Csf1–/– MC38 tumor cells implanted into WT and Foxp3YFP-Cre Pik3cdfl/fl mice. (C–H) Representative flow 
panels (C and D) and quantification of the CSF1R+ (E), Foxp3+ (F), CD8+ (G), and IFN-γ+ of CD8+ (H) immune cell infiltrates of WT and Csf1–/– MC38 
tumors isolated from the WT and Foxp3YFP-Cre Pik3cdfl/fl mice. Graphs show mean ± SEM of data from 10 individual mice per group. **P < 0.01;  
***P < 0.001; ****P < 0.0001 by 2-way ANOVA.
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TAMs and Foxp3+ Treg cells might contribute to monotherapy resistance (Figure 5A). To this end, 
C57BL/6 mice were orally dosed with 40 mg/kg PLX3397 and/or 100 mg/kg idelalisib daily from day 
7 after tumor implantation, when the tumors became palpable. Control mice received vehicle (0.5% w/v 
methylcellulose). Importantly, and consistent with compensatory immunosuppression driving therapy 
resistance to immune monotherapy, only tumors treated with the combination of  PLX3397 and idelalisib 
showed a statistically significant reduction in tumor growth and primary tumor mass (Figure 5, B and C). 
By contrast, single-agent PLX3397 or idelalisib-treated tumors grew at the same rates compared with the 
Figure 5. Combined inhibition of CSF1R and PI3Kδ effectively blocks tumor immunosuppression. (A) Graphical abstract. (B and C) In vivo growth curves (B) 
and tumor masses at day 21 (C) of WT mice orally treated with vehicle (0.5% methylcellulose) or 40 mg/kg PLX3397 or 100 mg/kg idelalisib or the combination 
of the 2 from day 7 following s.c. injections of MC38 cells. (D–I) Representative flow cytometry panels (left) and quantification (right) of the CSF1R+ (D and E), 
Foxp3+ (F and G), and CD8+ (H and I) immune cell infiltrates of WT mice treated with vehicle (0.5% methylcellulose) or 40 mg/kg PLX3397 or 100 mg/kg idelalisib 
or the combination of the two. Graphs show mean ± SEM of data from 10 individual mice per group. **P < 0.01; ***P < 0.001; ****P < 0.0001 by 2-way ANOVA.
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vehicle controls. As a confirmation of  the depletion of  TAMs by PLX3397, we detected a reduced pro-
portion of  CSF1R+ macrophages among intratumoral myeloid cells by flow cytometry (Figure 5, D and 
E). Similarly, flow cytometry confirmed the depletion of  Treg cells by idelalisib as a reduced proportion 
of  CD4+ Foxp3+ Treg cells among intratumoral lymphocytes (Figure 5, F and G). Consistent with a syn-
ergistic reversal of  immunosuppression, we detected an increase in CSF1R+ macrophages in idelalisib-
treated tumors (Figure 5, D and E), an increase in Foxp3+ Treg cells in PLX3397-treated tumors (Figure 
5, F and G), and a significant increase in the proportion of  CD8+ T lymphocytes among CD45+ cells in 
the MC38 tumors treated with the combination of  PLX3397 and idelalisib (Figure 5, H and I). Further, 
we detected similar synergistic effects when combining CSF1 blockade with PI3Kδ inhibition in the 
B16-F10 tumor model (Supplemental Figure 3, A and B). Collectively, these findings provide evidence of  
compensatory immunosuppression between CSF1R+ macrophages and PI3Kδ-driven Foxp3+ Treg cells 
and provide a rationale for combinatorial therapy using CSF1- and PI3Kδ-targeted approaches.
Discussion
TAMs and Treg cells are critical components of  the tumor microenvironment, and contribute to every 
aspect of  tumor growth and progression (5, 21, 30). Here, we provide evidence that Foxp3+ Treg cells and 
CSFR1+ TAMs form a partially redundant cellular network contributing robustness to tumor immunosup-
pression and a compensatory network contributing resistance to immunotherapy. Consistently, we found 
that tumor growth in the MC38 model was partially dependent upon CSF1 made by the tumor cells them-
selves and likely mediated through suppression of  CD8+ T cells by CSF1R+ TAMs. However, blocking 
this pathway alone resulted in increased accumulation of  Foxp3+ Treg cells inside the tumor and a modest 
effect on tumor growth. Conversely, depletion of  Foxp3+ Treg cells alone resulted in increased accumula-
tion of  CSF1R+ TAMs and, again, a modest effect on tumor growth. These results suggested the presence 
of  compensation between these 2 dominant immunosuppressive populations. Consistent with this hypoth-
esis, deletion of  both tumor-derived CSF1 and Foxp3+ Treg cells resulted in a dramatic influx of  CD8+ T 
cells, augmentation of  their function and a strikingly synergistic reduction in tumor growth.
Targeting the nontransformed tumor microenvironment is a promising approach to treat cancer, since 
it presents genetically stable targets for therapy (31, 32). However, the extent to which TAMs and Treg 
cells use common versus segregated molecular mechanisms to control CD8+ T cells or, indeed, com-
bine with other cell types to regulate tumorigenesis are still unclear. In line with this, clinical trials with 
PLX3397 used as a monotherapy have shown only limited potential to arrest solid tumor growth, possibly 
due to the development of  additional resistance mechanisms and acute toxicity problems when used close 
to maximum-tolerated doses (e.g., rebound myelopoiesis) (33). Similarly, idelalisib, capable of  disrupt-
ing Treg cell function, showed only limited potential to arrest solid tumor growth in preclinical studies 
when used as a monotherapy. Our results suggest that recruitment of  the main 2 immunosuppressive 
subsets capable of  limiting CD8+ T cell immunity, CSF1R+ macrophages and Foxp3+ Treg cells, can be 
responsible for maintaining significant immunosuppression in the absence of  the other. In support of  this, 
we show that PLX3397, at doses predicted to achieve substantial target engagement, had insignificant 
effects on the growth of  tumors in the MC38 model but was remarkably effective in combination with 
idelalisib, providing a strong rationale for exploring the combined pharmacological inhibition of  both 
TAMs and Treg cells by compounds currently in separate clinical development, and raising the prospect 
that these drugs might be effectively administered below their maximum-tolerated doses to reduce acute 
toxicity. Recently, several other groups have shown beneficial effects using combinations of  CSF1R inhibi-
tors with various other agents, including paclitaxel (34), radiation therapy (35), adoptive cell transfer (18, 
36), checkpoint inhibition therapy (16), and CXCR2 blockade (37). The most appropriate combinatorial 
approach will likely vary with the precise nature of  the tumor but, in principle, combined inhibition of  
CSF1R+ macrophages and Foxp3+ Treg cells carries the potential for an effective immunotherapy against 
a range of  tumors that rely upon immunosuppression for their survival and development.
Methods
Mice. C57BL/6 mice were obtained from the breeding colonies in the Biological Services Unit of  the Babra-
ham Institute. Foxp3DTR mice, expressing the human diphtheria toxin receptor and an eGFP reporter under 
the Foxp3 promoter, allowed specific depletion of  Foxp3+ cells upon administration of  diphtheria toxin 
(38). Foxp3YFP-Cre mice expressing a YFP-Cre fusion protein reporter from the Foxp3 promoter were crossed 
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with a mouse strain harboring loxP sites flanking alleles 1–9 of  the Pik3cd gene (Foxp3FYC-Cre Pik3cdfl/fl mice), 
allowing deletion of  PI3Kδ specifically in Foxp3+ cells (27). Rag2–/– mice were a gift from Marc Veldhoen 
(Instituto de Medicina Molecular, Lisboa, Portugal). In all experiments, mice were compared with appro-
priate age- and strain-matched controls. Mice were housed in the Biological Support Unit at the Babraham 
Institute under specific pathogen–free conditions.
Tumor cells. 4T1 mammary carcinoma, TRAMP-C1 prostate adenocarcinoma, and B16-F10 malignant 
melanoma cell lines were obtained from ATCC. LLC Lewis lung carcinoma cells were obtained from Mat-
thew Kraman (F-star Biotechnology, Cambridge, United Kingdom). The MC38 colon carcinoma cell line was 
obtained from Miguel Gaspar (F-star Biotechnology, Cambridge, United Kingdom), with permission from 
Mark Smyth (QIMR Berghofer, Brisbane, Australia). All tumor cells were maintained in culture in DMEM 
containing 10% FCS (GIBCO) and dissociated from culture flasks using Cell Dissociation Buffer (GIBCO).
ELISA. Levels of  CSF1 and TGF-β1 present within the supernatants of  the cells were measured using 
the Mouse M-CSF and Human TGF-β1 Quantikine ELISA kits (R&D Systems), in accordance with the 
manufacturer’s instructions.
Deletion of  Csf1. gRNA sequences directed against exon 1, 4, 5 of  the murine Csf1 gene were designed 
using the CHOPCHOP web tool for genome engineering (39). Analysis of  likely off-target genes was 
performed in silico. No genes directly involved in cell proliferation and differentiation were identified 
as off-targets. The following CRISPR guide oligonucleotides were ordered: 5′-CACCGGCTGCCCG-
TATGACCGCGCG-3′ (forward), 5′-AAACCGCGCGGTCATACGGGCAGCC-3′ (reverse), 5′-CAC-
CGGGTGTCCATTCCCAATCATG-3′ (forward), 5′-AAACCATGATTGGGAATGGACACCC-3′ 
(reverse), 5′-CACCGGAGTTCCTGGAGCCTCTCGG-3′ (forward) 5′-AAACCCGAGAGGCTCCAG-
GACCTCC-3′ (reverse), and subcloned into the pSpCas9 vector (PX458, Addgene) using the BbsI over-
hangs. After sequence verification of  the inserts, MC38 tumor cells were transfected with the pSpCas9Csf1 
and pBABEpuro vectors using Lipofectamine 2000 (ThermoFisher Scientific) transfection reagent. Cells 
were subsequently selected with 5 μg/ml puromycin for 72 hours and used for single-cell clone generation. 
Genomic modification of  single-cell clones was assessed by Western blotting and ELISA. Five different 
clones were tested in vitro and 2 independent clones were implanted in in vivo experiments.
Isolation of  BMDMs. Primary macrophages were isolated from long bones (femurs, tibia) of  WT mice 
essentially as described previously (40). Briefly, suspensions of  bone marrow cells were cultured for 48 
hours in complete medium (RPMI 1640 medium containing L-glutamine supplemented with 10% fetal 
bovine serum, 1% penicillin and streptomycin, 1 mM sodium pyruvate, 1% nonessential amino acids) in 
the presence of  10 ng/ml recombinant mouse CSF1 (Peprotech). Nonadherent cells (macrophage precur-
sors) were then plated at 0.5 million per cm2 and cultured in the presence of  10 ng/ml mouse CSF1 for 5 
more days with media changes and replacement of  the cytokines every 2 to 3 days. Flow cytometric analy-
sis of  the cells (to detect CD11b and F4/80 markers) revealed that greater than 97% were mature macro-
phages. In further experiments, CSF1 was supplied in the form of  purified protein (recombinant cytokine) 
or as a 10% conditioned medium derived from the different tumor cell lines.
Viability assays. PrestoBlue Cell Viability Reagent (Molecular Probes) was incubated with the cells for 
1 hour at 37°C and then fluorescence in the wells was detected on a PHERAstar FSX plate reader (BMG 
LabTech) using a 575/620 filter, with wells containing no cells set as a ‘blank’ standard according to the 
manufacturer’s instructions.
Isolation of  TAMs. A maximum of  1 gram of  tumor tissue per sample was placed into 2.5 ml of  tumor 
dissociation buffer (Tumor Dissociation Kit, Mouse, Miltenyi Biotec) and cut finely with scalpels. The 
minced tissue was transferred into gentleMACS C tubes (Miltenyi Biotec) and processed on a gentleMACS 
Dissociator (Miltenyi Biotec) according to the ‘soft/medium tissue’ protocol from the Tumor Dissocia-
tion Kit. Tubes were then placed in a shaking incubator at 37°C for 1 hour, and processed once more on 
the gentleMACS Dissociator. The digested tumors were filtered through 40-μM cell strainers (Falcon) to 
remove remaining solid tissue, washed through with PBS, and centrifuged at 500 g for 7 minutes. The cell 
pellets were then resuspended in PBS and cell counts determined on the CASY cell counter (OMNI Life 
Sciences). Tumor-infiltrating leukocytes were separated from cancer cells using a discontinuous Percoll 
(GE Healthcare) gradient of  40% Percoll (0.6 ml 10× PBS, 5.4 ml Percoll, and 9 ml DMEM) and 80% Per-
coll (1.2 ml 10× PBS, 10.8 ml Percoll, and 3 ml DMEM). Then, TAMs were isolated from other leukocytes 
by positive selection for CD115 (anti-mouse CD115-PE, clone AFS98, Biolegend) used at a 1:200 dilution 
in FACS buffer and incubated at 4°C for 30 minutes. After washing, the cells were incubated with anti-PE 
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microbeads (Miltenyi Biotec) at a 1:10 dilution in FACS buffer at 4°C for a further 20 minutes. Washed 
cells were passed through LS columns (Miltenyi Biotec) mounted on a μMACS separator (Miltenyi Bio-
tec), with the flowthrough containing the unlabeled leukocytes. Magnetically labeled CD115+ macrophages 
were eluted from the columns by firmly pushing the plunger into the column outside the magnet.
Lymphocyte isolation. Spleens were pushed through 40-μm cell strainers and washed with PBS. After 
centrifugation at 500 g for 5 minutes, the cell pellets were resuspended in 1 ml red blood cell lysis buffer 
(Sigma-Aldrich) and incubated at room temperature for 5 minutes. Cells were then washed and resus-
pended in PBS, and cell counts were determined on the CASY cell counter. CD8+ T cells were isolated from 
the spleen suspensions by negative selection against CD4+ T cells, B cells, natural killer (NK) cells, and 
antigen-presenting cells (APCs), respectively marked by anti-CD4 (clone RM4-5, Biolegend), anti-CD19 
(clone 6D5, Biolegend), anti-NK1.1 (clone PK136, Biolegend), and anti-MHC class II (clone M5/114.15-
2, Biolegend), all conjugated with FITC. These antibodies were applied to cells at a 1:200 dilution in FACS 
buffer and incubated at 4°C for 30 minutes. After washing, the cells were incubated with anti-FITC micro-
beads (Miltenyi Biotec) at a 1:10 dilution in FACS buffer at 4°C for a further 20 minutes. Washed cells were 
passed through LS columns mounted on the μMACS separator, with the flowthrough collected as CD8+ T 
cells of  90% to 95% purity.
Lymphocyte proliferation. CD8+ T cells were resuspended in RPMI 1640 medium (Invitrogen) supple-
mented with 10% FCS and a final concentration of  10 μM Cell Proliferation Dye 450 (eBioscience) was 
added to 1-ml aliquots of  lymphocytes with immediate vortexing to ensure rapid and homogeneous label-
ing of  cells. Cells were incubated at 37°C for 10 minutes, then washed 3 times with RPMI 1640 supple-
mented with 10% FCS. Fluorescent dye–labeled lymphocytes were cultured for 3 days in coculture with 
BMDMs or primary TAMs before antibody staining and analysis by flow cytometry.
Tumor models. Suspensions of  tumor cells were prepared in sterile PBS, and cell counts were deter-
mined on a CASY cell counter. MC38 (2 × 106) or B16-F10 (1 × 105) cells were administered in 200 μl by 
subcutaneous injection in the shaved left flank of  isoflurane-anesthetized mice. When tumors became pal-
pable (around day 7–10), tumor growth was monitored by caliper measurements every 2 to 3 days. Tumor 
volume (mm3) was calculated as length × width2. Mice bearing MC38 tumors were culled at 21 days after 
implantation. Mice bearing B16-F10 tumors were culled at 19 days after implantation. Any mice bearing 
tumors that approached or exceeded the terminal size limit (10% of  the weight of  the mouse at the start of  
the study) during the course of  the study were culled and excluded from the study. Tumors were collected 
into cold PBS at the end of  the study and weights recorded prior to further processing.
Flow cytometry. Surface stains were carried out in PBS containing 2% FCS (FACS buffer) for 30 min-
utes at 4°C. All of  the following antibodies were used at a 1:200 dilution: anti-mouse CD8-BV711 (clone 
53-6.7), CD11b-APC (clone M1/70), CD45-BV650 (clone 30-F11), CD115-PE (clone AFS98), CD274-
BV605 (clone 10F.9G2), F4/80-PEcy7 (clone BM8), Ly6C-AF700 (clone HK1.4), IFN-γ-BV510 (clone 
XMG1.2, all from Biolegend); CD206-PE (clone MR6F3), CD163-PerCP eF710 (clone TNKUPJ), MHC 
class II-APC (M5/114.15.2, all from eBioscience). Fixation and permeabilization for intracellular staining 
was carried out with the Foxp3/Transcription Factor Staining Buffer set (eBioscience), with a 15-minute 
fixation at room temperature, followed by intracellular staining in permeabilization buffer for 30 minutes 
at 4°C. Unless otherwise stated, in assays where cells are fixed, Fixable Viability Dye eFluor 780 (eBiosci-
ence) was added to the surface stain solution at a 1:3,000 dilution. Samples were acquired on the BD Fort-
essa analyzers in the Babraham Institute Flow Core Facility. Data collected were analyzed using FlowJo 
software (Tree Star).
In vivo inhibitor and depleting antibody treatments. PLX3397 and idelalisib (both from Selleckchem) 
were administered orally once per day at 40 mg/kg and 100 mg/kg, respectively, from day 7 after tumor 
implantation. Methylcellulose (0.5% w/v) was used as the vehicle control. B16-F10 tumor–bearing mice 
were treated intraperitoneally (i.p.) with 150 μg InVivoMAb anti-mouse CSF1 antibody (clone 5A1, Bio 
X Cell) on days 3, 7, 10, 14, and 17 after tumor implantation. The isotype control used in this experi-
ment was rat IgG1 (clone HRPN, Bio X Cell). Diphtheria toxin from Corynebacterium diphtheriae (Sigma-
Aldrich) was obtained in lyophilized powder form, and reconstituted in 0.5 ml sterile ddH2O according 
to the manufacturer’s instructions. Solutions for injection were made up in sterile PBS to a dose of  
25 μg/kg, separately calculated based on average weights of  male and female mice in each cohort. To 
achieve transient depletion of  Treg cells in Foxp3DTR mice, diphtheria toxin was administered to the 
peritoneum in a 100 μl volume, with mice under inhalation anesthesia, on days 3, 7, 10, 14, and 17 after 
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tumor implantation. Tumor growth was monitored as described above, and processing of  tissues at the 
end of  the experiment followed the same method as detailed in previous sections.
Study approval. All animal work was performed under Home Office UK Project license PPL 70/8100.
Statistics. Data were compared using a 2-tailed, unpaired Student’s t test or 2-way, repeated-measures 
ANOVA with Bonferroni’s post hoc test (GraphPad Prism software). Differences with P values of  < 0.05 
were considered significant: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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